Autolus Therapeutics (AUTL) Net Cash Flow (2017 - 2025)

Autolus Therapeutics (AUTL) has reported Net Cash Flow for 9 consecutive years, with $17.4 million the latest figure, recorded in Q4 2025.

• Quarterly Net Cash Flow rose 104.45% year-over-year to $17.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$129.4 million (down 1048.72% YoY) and the FY2025 annual result came in at -$129.4 million, down 1048.72% from the prior year.
• Net Cash Flow rose to $17.4 million in Q4 2025 per AUTL's latest filing, from -$34.1 million in the prior quarter.
• Over the last five years, Net Cash Flow for AUTL reached as high as $520.4 million in Q1 2024 and fell as low as -$391.5 million in Q4 2024.
• A 5-year average of -$2.0 million and a median of -$35.0 million in 2022 frame the typical range for Net Cash Flow.
• The largest YoY upside for Net Cash Flow was 1213.57% in 2024 against a maximum downside of 1389.39% in 2024.
• Year by year, Net Cash Flow stood at $136.7 million in 2021, then soared by 52.42% to $208.3 million in 2022, then tumbled by 112.62% to -$26.3 million in 2023, then tumbled by 1389.39% to -$391.5 million in 2024, then jumped by 104.45% to $17.4 million in 2025.
• According to Business Quant data, Net Cash Flow over the past three periods registered $17.4 million, -$34.1 million, and $22.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.